ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt

1997 • 1,051 citations

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

2001 • 995 citations

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

2000 • 766 citations

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

2001 • 642 citations

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1992 • 619 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 490 citations

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

2001 • 414 citations

Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.

1999 • 353 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 244 citations

A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC)

2001 • 194 citations

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

2001 • 118 citations

Kinase Inhibitors in Cancer Therapy

2000 • 87 citations

Differential expression of epidermal growth factor receptor in human head and neck cancers

1998 • 86 citations

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839

2001 • 83 citations

ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT

1997 • 70 citations

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

2002 • 67 citations

The epidermal growth factor receptor in breast cancer.

1997 • 64 citations

Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas.

1997 • 42 citations

Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells.

2000 • 38 citations

Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells

2000 • 27 citations

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839

2001 • 10 citations

Immunohistochemical markers in the morphological diagnosis of lung carcinoma.

1997 • 5 citations